Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-02-05
2010-02-16
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07662976
ABSTRACT:
Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
REFERENCES:
patent: 3646201 (1972-02-01), Kallianos et al.
patent: 4005108 (1977-01-01), Kupchan
patent: 5192817 (1993-03-01), Takaishi et al.
patent: 5294443 (1994-03-01), Lipsky et al.
patent: 5430054 (1995-07-01), Qian et al.
patent: 5468772 (1995-11-01), Xu et al.
patent: 5565569 (1996-10-01), Tsujihara et al.
patent: 5580562 (1996-12-01), Lipsky et al.
patent: 5648376 (1997-07-01), Strobel et al.
patent: 5663335 (1997-09-01), Qi et al.
patent: 5759550 (1998-06-01), Weidmann et al.
patent: 5843452 (1998-12-01), Weidmann et al.
patent: 5919816 (1999-07-01), Hausheer et al.
patent: 5962516 (1999-10-01), Qi et al.
patent: 5972998 (1999-10-01), Jung et al.
patent: 6004999 (1999-12-01), Jung et al.
patent: 6150539 (2000-11-01), Musser
patent: 6294546 (2001-09-01), Rosen et al.
patent: 6329148 (2001-12-01), Rosen et al.
patent: 6458537 (2002-10-01), Staub et al.
patent: 6537984 (2003-03-01), Rosen et al.
patent: 6548537 (2003-04-01), Dai et al.
patent: 6569893 (2003-05-01), Dai et al.
patent: 6599499 (2003-07-01), Rosen et al.
patent: 6620843 (2003-09-01), Fidler et al.
patent: 6777441 (2004-08-01), Wang et al.
patent: 6943259 (2005-09-01), Dai et al.
patent: 7019151 (2006-03-01), Dai et al.
patent: 7098348 (2006-08-01), Dai et al.
patent: 7417069 (2008-08-01), Dai et al.
patent: 2002/0077350 (2002-06-01), Babish et al.
patent: 2004/0018260 (2004-01-01), Ren et al.
patent: 2004/0152767 (2004-08-01), Dai et al.
patent: 2004/0198808 (2004-10-01), Dai et al.
patent: 2004/0235943 (2004-11-01), Dai et al.
patent: 2005/0288645 (2005-12-01), LaVon
patent: 2007/0244080 (2007-10-01), Fidler et al.
patent: 2007/0249048 (2007-10-01), Dai et al.
patent: 2007/0282114 (2007-12-01), An et al.
patent: 2008/0193948 (2008-08-01), Fidler et al.
patent: 2008/0287530 (2008-11-01), Yuan et al.
patent: 1052859 (1991-07-01), None
patent: 1317248 (2001-10-01), None
patent: 0 156 643 (1985-10-01), None
patent: 61-085319 (1986-04-01), None
patent: 03 178977 (1991-08-01), None
patent: WO 94/26265 (1994-11-01), None
patent: WO 97/31920 (1997-09-01), None
patent: WO 97/31921 (1997-09-01), None
patent: WO 98/52933 (1998-11-01), None
patent: WO 98/52951 (1998-11-01), None
patent: WO 00/12483 (2000-03-01), None
patent: WO 00/63212 (2000-10-01), None
patent: WO 01/15707 (2001-03-01), None
patent: WO 02/56835 (2002-07-01), None
patent: WO 02/070472 (2002-09-01), None
patent: WO 02/074759 (2002-09-01), None
patent: WO 03/101951 (2003-12-01), None
patent: WO 2005/000291 (2005-01-01), None
patent: WO 2005/020887 (2005-03-01), None
patent: WO 2005/062913 (2005-07-01), None
patent: WO 2005/084365 (2005-09-01), None
patent: WO 2006/012204 (2006-02-01), None
patent: WO 09/23201 (2009-02-01), None
Aumuller, G. et al., “Intermediate filaments in sertoli cells”,Microscopy Research and Technique, 20:50-72(1992).
Becker, K. et al., “Thioredoxin reductase as a pathophysiological factor and drug target”,Eur. J. Biochem., 267(20):6118-6125 (2000).
Berg, D. et al., “14-3-3 Proteins in the nervous system”,Nature Reviews Neuroscience,. 4:752-62 (2003).
Britton, R. et al., “New okadaic acid analogues from the marine sponge Merriamum oxeato and their effect on mitosis”,J. Nat. Prod., 66:838-43 (2003).
Chang, W-T. et al., “Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway”,The Journal of Biological Chemistry, 276(3):2221-2227 (2001).
Chen et al., “Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model”,Transplantation, 73(1):115 (2002).
Chen et al., “Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion”,Transplantation, 70(10):1442-1447 (2000).
Cheng et al., “Research on extraction technology of Tripterygium”,Chinese Journal of Pharmaceuticals, 21(10):435-436 (No English translation) (1990).
Cheng, X.X. et al., Yao Xue Xue Bao,ACTA Pharmaceutica Sinica, 37:339-342 (2002) (English Abstract translation).
Englebienne et al.,Drug Design Reviews -Online, “The Place of Biosteric Sila Substitution in Drug Design”, 2 pages (2005).
Fidler, J.M. et al., “PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy”,Molecular Cancer Therapeutics, 2(9):855-62 (2003).
Fidler, J.M. et al., “Immunosuppressive activity of the Chinese medicinal plantTripterygium wilfordii. III. Suppression of graft-versus-host disease in murine allogeneic bone marrow transplantation by the PG27 extract”,Transplantation, 74(4):445-457 (2002).
Fruman, D.A. et al., “Phosphoinositide Kinases”,Ann. Rev. Biochem., 67:481-507 (1998).
Fu et al., “14-3-3 Proteins: Structure, Function, and regulation”,Ann. Rev. Pharmacol. Toxicol., 40:617-47 (2000).
Gabbiani, G., “The myofibroblast in wound healing and fibrocontractive diseases”,Journal of Pathology, 200:500-503 (2003).
Garcia, A. et al., “Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis”,Biochimie, 85:721-726 (2003).
Gilles, C. et al., “Transactivation of vimentin by beta-catenin in human breast cancer cells”,Cancer Research, 63(10):2658-2664 (2003).
Gleichmann, E. et al., “Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases”,Immunology Today, 5(11):324-332 (1984).
Goto, Y. et al., “Augmented cytoplasmic Smad4 induces acceleration of TGF-beta1 signaling in renal tubulointerstitial cells of hereditary nephrotic ICGN mice with chronic renal fibrosis; possible role for myofibroblastic differentiation”,Cell Tissue Res., 315:209-221 (2004).
Gross, T.J. and Hunninghake, G.W., “Idiopathic pulmonary fibrosis”,N. Engl. J. Med., 345(7):517-525 (2001).
He, Q. et al., “Neuroprotective eggects ofTripterygium wilfordii Hook FMonomer T10on glutamate induced PC12 cell line damage and its mechanism”,Beijing Da Xue Xue Bao, Journal of Peking University(Health Sciences), 35(3):252-5 (Jun. 2003) (English Abstract Translation).
Houtman, J.C. et al., “Early phosphorylation kinetics of proteins involved in proximal TCR-mediated signaling pathways”,Journal of Immunology, 175(4):2449-2458 (2005).
Jiang, X-H. et al., “Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells”,Oncogene, 20(55):8009-8018 (2001).
Jerums, G. at al., “Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease”,Archives of Biochemistry and Biophysics, 419(1):55-62 (2003).
Jiarun, Z. et al., “Screening of active anti-inflammatory, immunosuppressive and antifertility components ofTripterygium wilfordii”, ACTA Academiae Medicinae Sinicae 13(6):391-397 (English Abstract only) (1991).
Jones, S.L. et al. “A role for the actin-bundling protein L-plastin in the regulation of leukocyte integrin function”,Proc. Natl. Acad. Sci. USA, 95(16):9331-9336 (1998).
Kershenobich, D. et al., “Concise Review: Liver fibrosis and inflammation. A review”,Annals of. Hepatology, 2(4):159-163 (2003).
Keyser, F. D. et al., “The role of T cells in Rheumatoid Arthritis”,Clinical Rgeumatology, 14(Suppl 2):5-9 (1995).
Khanna, A.K. and Mehta, M.R., “Targeted in vitro and in vivo gene transfer into T lymphocytes: potential of direct inhibition of allo-immune activation”,BMC Immunology, 7(26):1-10 (2006).
Korngold, B. and Sprent, J. “Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility ba
Dai Dongcheng
Lennox Edwin S.
Musser John H.
Chandrakumar Nizal S
Dehlinger Peter J.
King & Spalding LLP
Myers Fitch Susan J.
Pharmagenesis, Inc.
LandOfFree
Triptolide derivatives for modulation of apoptosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triptolide derivatives for modulation of apoptosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triptolide derivatives for modulation of apoptosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203881